InflaRx (IFRX) Total Debt (2020 - 2026)

InflaRx (IFRX) posted Total Debt of $5.2 million for Q2 2025, up 3465.43% sequentially from $144451.4 in Q3 2022.

InflaRx (IFRX) Total Debt (2020 - 2026) Analysis & Trends

InflaRx has reported Total Debt for 4 years, with the latest figure at $5.2 million in Q2 2025.

Quarterly Total Debt changed N/A year-over-year to $5.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $5.2 million (changed N/A YoY) and the FY2021 annual result came in at $163552.6, up 21.67% from the prior year.
Total Debt rose to $5.2 million in Q2 2025 per IFRX's latest filing, from $144451.4 in the prior quarter.
Over five years, Total Debt peaked at $5.2 million in Q2 2025 and troughed at $139078.0 in Q2 2022.
A 3-year average of $903141.8 and a median of $150512.3 in 2021 frame the typical range for Total Debt.
The sharpest annual moves came in 2021 and 2022: Total Debt rose 12.64% in 2021, then plunged 65.88% in 2022.
Over 3 years, Total Debt stood at $158103.6 in 2021, then retreated by 8.63% to $144451.4 in 2022, then jumped by 3465.43% to $5.2 million in 2025.
According to Business Quant data, Total Debt over the past three periods registered $5.2 million, $144451.4, and $139078.0 for Q2 2025, Q3 2022, and Q2 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.34 Bn
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn	-

Download Data